Immune Checkpoint Inhibitor–Based Therapy as a Backbone in Cancer Treatment
Presented by Krista M. Rubin,(1) MS, FNP-BC, and Anthony J. Olszanski,(2) MD, RPh
From (1)Massachusetts General Hospital Cancer Center, Boston, Massachusetts; (2)Fox Chase Cancer Center of Temple Health, Philadelphia, Pennsylvania
Presenters’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2020;11(3):231–233 |
© 2020 Harborside™
At JADPRO Live 2019, Krista M. Rubin, MS, FNP-BC, and Anthony J. Olszanski, MD, RPh, reviewed the basic concepts of immunotherapy and the current treatment landscape, and discussed emerging data for immune checkpoint inhibitor–based combinations that are being explored in late-stage clinical trials.
For access to the full length article, please sign in